Akcea and Ionis Announce Positive Phase 2 Clinical Trial Results

Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), announced positive topline clinical trial results on September 24. The Phase 2 clinical trial is studying the effect of AKCEA-APO(a)-LRx on patients with established cardiovascular disease and elevated levels of lipoprotein(a), known as Lp(a). The goal of the Phase 2 clinical study was to establish dosing amount and frequency for the Phase 3 outcomes study. The Phase 2 clinical trial showed that Akcea’s drug lowered Lp(a) while maintaining a favorable safety and tolerability profile.

 

Sonal sent an alert to subscribers at 7:00 am. The next trade took place at 8:12 am for $29. The stock price faded back at the market open to $28.13. Then, the stock price climbed to close at $33.08 with a 14% gain on the event day.

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!